vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and STONERIDGE INC (SRI). Click either name above to swap in a different company.
STONERIDGE INC is the larger business by last-quarter revenue ($205.2M vs $139.2M, roughly 1.5× ADMA BIOLOGICS, INC.). On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs -6.0%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $2.6M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs -7.4%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Stoneridge Inc is a global designer and manufacturer of advanced electrical and electronic components, integrated systems, and sensor solutions. It serves automotive, commercial vehicle, off-highway, and aerospace sectors, delivering products that boost vehicle safety, efficiency, connectivity, and environmental performance across key global markets.
ADMA vs SRI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $205.2M |
| Net Profit | $49.4M | — |
| Gross Margin | 63.8% | 16.2% |
| Operating Margin | 45.1% | -14.4% |
| Net Margin | 35.5% | — |
| Revenue YoY | 18.4% | -6.0% |
| Net Profit YoY | -55.9% | — |
| EPS (diluted) | $0.20 | $-2.76 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $205.2M | ||
| Q3 25 | $134.2M | $210.3M | ||
| Q2 25 | $122.0M | $228.0M | ||
| Q1 25 | $114.8M | $217.9M | ||
| Q4 24 | $117.5M | $218.2M | ||
| Q3 24 | $119.8M | $213.8M | ||
| Q2 24 | $107.2M | $237.1M | ||
| Q1 24 | $81.9M | $239.2M |
| Q4 25 | $49.4M | — | ||
| Q3 25 | $36.4M | $-9.4M | ||
| Q2 25 | $34.2M | $-9.4M | ||
| Q1 25 | $26.9M | $-7.2M | ||
| Q4 24 | $111.9M | — | ||
| Q3 24 | $35.9M | $-7.1M | ||
| Q2 24 | $32.1M | $2.8M | ||
| Q1 24 | $17.8M | $-6.1M |
| Q4 25 | 63.8% | 16.2% | ||
| Q3 25 | 56.3% | 20.3% | ||
| Q2 25 | 55.1% | 21.5% | ||
| Q1 25 | 53.2% | 21.2% | ||
| Q4 24 | 53.9% | 19.5% | ||
| Q3 24 | 49.8% | 20.8% | ||
| Q2 24 | 53.6% | 22.7% | ||
| Q1 24 | 47.8% | 20.2% |
| Q4 25 | 45.1% | -14.4% | ||
| Q3 25 | 38.0% | -1.6% | ||
| Q2 25 | 35.1% | -1.1% | ||
| Q1 25 | 30.4% | -1.5% | ||
| Q4 24 | 32.6% | -2.0% | ||
| Q3 24 | 33.1% | 0.1% | ||
| Q2 24 | 36.6% | 1.4% | ||
| Q1 24 | 26.7% | 0.1% |
| Q4 25 | 35.5% | — | ||
| Q3 25 | 27.1% | -4.5% | ||
| Q2 25 | 28.1% | -4.1% | ||
| Q1 25 | 23.4% | -3.3% | ||
| Q4 24 | 95.2% | — | ||
| Q3 24 | 30.0% | -3.3% | ||
| Q2 24 | 29.9% | 1.2% | ||
| Q1 24 | 21.7% | -2.6% |
| Q4 25 | $0.20 | $-2.76 | ||
| Q3 25 | $0.15 | $-0.34 | ||
| Q2 25 | $0.14 | $-0.34 | ||
| Q1 25 | $0.11 | $-0.26 | ||
| Q4 24 | $0.45 | $-0.22 | ||
| Q3 24 | $0.15 | $-0.26 | ||
| Q2 24 | $0.13 | $0.10 | ||
| Q1 24 | $0.08 | $-0.22 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $66.3M |
| Total DebtLower is stronger | $72.1M | $180.9M |
| Stockholders' EquityBook value | $477.3M | $179.8M |
| Total Assets | $624.2M | $551.2M |
| Debt / EquityLower = less leverage | 0.15× | 1.01× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $66.3M | ||
| Q3 25 | $61.4M | $54.0M | ||
| Q2 25 | $90.3M | $49.8M | ||
| Q1 25 | $71.6M | $79.1M | ||
| Q4 24 | $103.1M | $71.8M | ||
| Q3 24 | $86.7M | $54.1M | ||
| Q2 24 | $88.2M | $42.1M | ||
| Q1 24 | $45.3M | $48.4M |
| Q4 25 | $72.1M | $180.9M | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | $201.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $477.3M | $179.8M | ||
| Q3 25 | $431.2M | $251.2M | ||
| Q2 25 | $398.3M | $260.5M | ||
| Q1 25 | $373.4M | $253.1M | ||
| Q4 24 | $349.0M | $245.3M | ||
| Q3 24 | $231.9M | $271.4M | ||
| Q2 24 | $188.3M | $270.5M | ||
| Q1 24 | $153.7M | $277.3M |
| Q4 25 | $624.2M | $551.2M | ||
| Q3 25 | $568.7M | $632.1M | ||
| Q2 25 | $558.4M | $639.4M | ||
| Q1 25 | $510.6M | $657.4M | ||
| Q4 24 | $488.7M | $621.6M | ||
| Q3 24 | $390.6M | $662.5M | ||
| Q2 24 | $376.4M | $666.7M | ||
| Q1 24 | $350.9M | $675.4M |
| Q4 25 | 0.15× | 1.01× | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | 0.82× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $8.8M |
| Free Cash FlowOCF − Capex | $34.6M | $2.6M |
| FCF MarginFCF / Revenue | 24.8% | 1.3% |
| Capex IntensityCapex / Revenue | 0.8% | 3.0% |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $12.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $8.8M | ||
| Q3 25 | $13.3M | $3.6M | ||
| Q2 25 | $21.1M | $10.7M | ||
| Q1 25 | $-19.7M | $10.9M | ||
| Q4 24 | $50.2M | $19.2M | ||
| Q3 24 | $25.0M | $10.8M | ||
| Q2 24 | $45.6M | $8.7M | ||
| Q1 24 | $-2.2M | $9.1M |
| Q4 25 | $34.6M | $2.6M | ||
| Q3 25 | $-1.1M | $-2.7M | ||
| Q2 25 | $18.7M | $7.4M | ||
| Q1 25 | $-24.4M | $4.8M | ||
| Q4 24 | $47.5M | $14.0M | ||
| Q3 24 | $24.0M | $4.6M | ||
| Q2 24 | $43.6M | $1.5M | ||
| Q1 24 | $-4.6M | $3.3M |
| Q4 25 | 24.8% | 1.3% | ||
| Q3 25 | -0.8% | -1.3% | ||
| Q2 25 | 15.3% | 3.3% | ||
| Q1 25 | -21.2% | 2.2% | ||
| Q4 24 | 40.4% | 6.4% | ||
| Q3 24 | 20.0% | 2.2% | ||
| Q2 24 | 40.7% | 0.6% | ||
| Q1 24 | -5.6% | 1.4% |
| Q4 25 | 0.8% | 3.0% | ||
| Q3 25 | 10.7% | 3.0% | ||
| Q2 25 | 2.0% | 1.4% | ||
| Q1 25 | 4.1% | 2.8% | ||
| Q4 24 | 2.3% | 2.4% | ||
| Q3 24 | 0.9% | 2.9% | ||
| Q2 24 | 1.9% | 3.0% | ||
| Q1 24 | 2.9% | 2.4% |
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 1.42× | 3.11× | ||
| Q1 24 | -0.12× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
SRI
| Control Devices | $51.7M | 25% |
| Electronics | $38.0M | 19% |
| EE | $34.2M | 17% |
| SE | $28.6M | 14% |
| NL | $24.5M | 12% |
| Stoneridge Brazil | $14.1M | 7% |
| Asia Pacific | $13.1M | 6% |
